Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

BRDG1 Inhibitors

BRDG1 inhibitors is a class of chemical compounds that have been the subject of extensive investigation due to their distinctive capability to exert regulatory control over the BRDG1 protein. BRDG1, intricately entwined in the complex web of B-cell receptor downstream signaling pathways, assumes a pivotal role in orchestrating various cellular processes pivotal for immune responses. These inhibitors are meticulously structured to exclusively engage with BRDG1, thereby orchestrating a finely tuned modulation of its multifaceted functions. Operating through intricate binding interactions, BRDG1 inhibitors undertake the formidable task of overseeing and orchestrating the intricate landscape of biological pathways and molecular dialogues associated with the BRDG1 protein. The relentless pursuit of unraveling the molecular nuances of BRDG1 and its intricate interplay with its inhibitors has culminated in a multifaceted understanding of their mode of interaction and subsequent impact. Researchers are fervently dedicated to illuminating the molecular intricacies underpinning the interaction dynamics between BRDG1 and its inhibitors, thereby unraveling the precise mechanisms that govern their activity. This fervent exploration into the intricate interplay between BRDG1 and its inhibitors significantly contributes to the broader landscape of cellular signaling. Moreover, it imparts an essential arsenal of investigative tools that hold the potential to unravel the enigmatic functional roles of BRDG1 within the broader tapestry of cellular physiology. As such, the study and scrutiny of BRDG1 inhibitors not only unlock deeper insights into the intricate choreography of cellular signaling pathways but also hold promise for uncovering novel avenues for cellular modulation and intervention.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

While primarily used as a tyrosine kinase inhibitor for certain cancers, imatinib has been investigated for its effects on B-cell receptor signaling pathways. It might indirectly influence BRDG1 activity.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a tyrosine kinase inhibitor primarily used in cancer research. It could impact B-cell receptor signaling pathways and potentially affect BRDG1-mediated processes.

R788

901119-35-5sc-364597
sc-364597A
2 mg
50 mg
$405.00
$4000.00
2
(0)

Apart from its Syk inhibitory effects, fostamatinib has been explored for its broader impacts on B-cell signaling, which could influence BRDG1 activity.

Tirabrutinib

1351636-18-4sc-507435
10 mg
$138.00
(0)

A BTK inhibitor, tirabrutinib has been investigated for its effects on B-cell signaling pathways, which could indirectly affect BRDG1-mediated processes.

Acalabrutinib

1420477-60-6sc-507392
250 mg
$255.00
(0)

A BTK inhibitor with potential anti-inflammatory effects, ACP-196 could influence B-cell receptor signaling pathways and related proteins like BRDG1.

TGR-1202

1532533-67-7sc-507436
25 mg
$286.00
(0)

This compound has been developed as a dual inhibitor of PI3K-delta and CK1-epsilon. Since PI3K signaling is closely related to B-cell receptor pathways, umbralisib could indirectly affect BRDG1-mediated processes.